Crossmark

Ixazomib or Lenalidomide combined with cyclophosphamide and dexamethasone in the treatment of elderly transplant-ineligible newly diagnosed multiple myeloma

Crossref DOI link: https://doi.org/10.1038/s41598-025-91126-5

Published Online: 2025-02-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wang, Yan

Liu, Yuan-Fang

Jin, Shi-Wei

Tao, Yi

Zhang, Wei-Ping

Chen, Jian-Lin

Jiang, Song-Fu

Mi, Jian-Qing
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82070227)
License Information

Text and Data Mining valid from 2025-02-24

Version of Record valid from 2025-02-24
More Information

Article History

Received: 30 December 2024

Accepted: 18 February 2025

First Online: 24 February 2025

Declarations

:

: The Internal Review Board (IRB) of Ruijin Hospital approved this study. Informed consent was obtained from all study participants. The study was carried out following the Declaration of Helsinki.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below